Dr. John Cush RheumNow
7 years 5 months ago
Animal data suggests targeting of neutrophils in APS may mitigate thrombotic disease. Adenosine recept agonists suppresses aPL Ab-mediated NETosis & reduces IVC thrombosis. Same shown for dipyridamole (incr. adenosine & cAMP breakdown). https://t.co/BHACehh0lb
Dr. John Cush RheumNow
7 years 5 months ago
Comparing nearly 230,000 Taiwanese with and without gout shows gout pts have more psoriasis (1.6% vs 1.1%; adjusted OR 1.30; 1.20-1.42) and psoriatic arthritis (0.3% v 0.1%; aOR 2.50; 1.95-3.22). https://t.co/c1ZVy5E6vk
RheumNow Live Preview with Dr. Ken Kalunian (New Criteria, Guidelines & Outcomes in Lupus)
Preview of Dr. Ken Kalunian's lecture on New Criteria, Guidelines and Outcomes in Lupus at the 2019 RheumNow Live meeting.
Dr. John Cush RheumNow
7 years 5 months ago
Vote on the NEJM Question of the week - Which one of the following vaccination regimens is recommended for a 62-year-old woman with systemic lupus erythematosus who is being treated with prednisone 5 mg daily? Go here to vote https://t.co/27an4cVdqv
Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
The Journal of Rheumatology jrheum
7 years 5 months ago
Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis https://t.co/kuX8X6l99V https://t.co/p4kr42piYy
Dr. John Cush RheumNow
7 years 5 months ago
Another Step beyond the DEAs Take Back program that ocurrs twice a year (April and October), including Saturday April 27th - see my earlier tweet on this today https://t.co/WPt6VIboMW
A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).
The INTREPAD trial was a 2-year double-masked prevention trial, that enrolled 195 AD who were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS).
The Annals of Internal Medicine reports a metanalysis done to examine the optimal length of long-term osteoporosis drug treatment (ODT) and whether harms are associated with long-term ODT and while the ODT benefits are clear, the risk of rare harms and need for drug holidays is less certain.
Dr. John Cush RheumNow
7 years 5 months ago
Results from Nationwide Inpatient Sample Database (2003–11) finds 31,439 obstetric hosp. in RA women who had a higher maternal age (30.5 yrs) & significantly more HTN, premature membr. rupture, antepartum hemorrhage, preterm delivery, IUGR & C sections https://t.co/pz5uQH5rrx
Dr. John Cush RheumNow
7 years 5 months ago
Swedish population study compared 8109 RA pts and 11562 full siblings to the general population, finding the risk of acute coronary syndrome to be increased in RA (HR 1.46; 1.28 -1.67) and RA Sibs (HR 1.22; 1.09 - 1.38) w/ risks confined to seropositives https://t.co/oYUP3jgY60
Dr. John Cush RheumNow
7 years 5 months ago
This Saturday is National Prescription Drug Take-Back Day where you can dispose of old, unused, unwanted (Potentially harmful) prescription medicines. These are run by your local police or DPS. Use this link to find out where in your town https://t.co/eae3l6OtqC
Dr. John Cush RheumNow
7 years 5 months ago
Danish study of 92 355 adults compared Fx rates between new users of denosumab (DEN) or alendronate - finds no advantage for DEN for hip Fx (aHR 1.08; 0.92-1.28) or any Fx (aHR 0.92; 0.83-1.02). Data doesnt support preference for DEN in high risk pts. https://t.co/dpyRF9VxH6
